Identification of Apo-A1 as a biomarker for early diagnosis of bladder transitional cell carcinoma

Proteome Science

Volumn 9, Issue , 2011, Pages

  Li, Hongjie ^a   Li, Changying ^b   Wu, Huili ^c   Zhang, Ting ^b   Wang, Jin ^b   Wang, Shixin ^c   Chang, Jiwu ^b  

^a HEBEI UNITED UNIVERSITY   (China)

^b SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^c MEDICAL COLLEGE OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CLUSTERIN; FIBRINOGEN; HAPTOGLOBIN; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; BIOINFORMATICS; BLADDER CANCER; BLADDER CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MASS SPECTROMETRY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; TWO DIMENSIONAL ELECTROPHORESIS; URINALYSIS;

EID: 79955093959     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-9-21     Document Type: Article

References (34)

1. Kausch I, Böhle A. Bladder cancer II Molecular aspects and diagnosis. Eur Urol 2001, 5:498-506.
2. Karakiewicz PI, Benayoun S, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Marberger MJ, Shariat SF. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. BJU Int 2006, 5:997-1001.
3. Mitropoulos D, Kiroudi-Voulgari A, Nikolopoulos P, Manousakas T, Zervas A. Accuracy of cystoscopy in predicting histologic features of bladder lesions. J Endourol 2005, 7:861-864.
4. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cnacer 2003, 4:267-275.
5. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005, 17:4589-4596.
6. Görg A, Obermaier C, Boguth G, Harder A, Scheibe B, Wildgruber R, Weiss W. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 2000, 6:1037-1053.
7. Irmak S, Tilki D, Heukeshoven J, Oliveira-Ferrer L, Friedrich M, Huland H, Ergün S. Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics 2005, 16:4296-4304.
8. Saito M, Kimoto M, Araki T, Shimada Y, Fujii R, Oofusa K, Hide M, Usui T, Yoshizato K. Proteome Analysis of Gelatin-Bound Urinary Proteins from Patients with Bladder Cancers. Eur Urol 2005, 5:865-871.
9. Halling KC, King W, Sokolova IA, Karnes RJ, Meyer RG, Powell EL, Sebo TJ, Cheville JC, Clayton AC, Krajnik KL, Ebert TA, Nelson RE, Burkhardt HM, Ramakumar S, Stewart CS, Pankratz VS, Lieber MM, Blute ML, Zincke H, Seelig SA, Jenkins RB, O'Kane DJ. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002, 5:2001-2006.
10. Konety BR, Nguyen TS, Brenes G, Sholder A, Lewis N, Bastacky S, Potter DM, Getzenberg RH. Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer. J Urol 2000, 3(Pt 1):634-639.
11. Eissa S, Swellam M, Sadek M, Mourad MS, El Ahmady O, Khalifa A. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors. J Urol 2002, 2:465-469.
12. Koss LG. Bladder cancer from a perspective of 40 years. J Cell Biochem Suppl 1992, 16:23-29.
13. Jones PA, Droller MJ. Pathways of development and progression in bladder cancer: New orrelations between observations and molecular mechanisms. Semin Urol 1993, 4:177-192.
14. Wang HT, Chang JW. Molecular pathology of low malignant bladder transitional cell carcinoma: a current perspective. Histol Histopathol 2005, 1:147-153.
15. Wang HT, Ma FL, Ma XB, Han RF, Zhang YB, Chang JW. Differential gene expression profiling in aggressive bladder transitional cell carcinoma compared to the adjacent microscopically normal urothelium by microdissection-SMART cDNA PCR-SSH. Cancer Biol Ther 2006, 1:104-110.
16. Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmütte C, Yang AS, Cote R. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 1994, 3:784-788.
17. Zhang ZT, Pak J, Huang HY, Shapiro E, Sun TT, Pellicer A, Wu XR. Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation. Oncogene 2001, 16:1973-1980.
18. Chen YT, Chen CL, Chen HW, Chung T, Wu CC, Chen CD, Hsu CW, Chen MC, Tsui KH, Chang PL, Chang YS, Yu JS. Discovery of Novel Bladder Cancer Biomarkers by Comparative Urine Proteomics Using iTRAQ Technology. J Proteome Res 2010, 9:5803-5815. 10.1021/pr100576x, 20806971.
19. Grundy SM, Vega GL. Role of Apolipoprotein Levels in Clinical Practice. Arch Int Med 1990, 8:1579-1582.
20. Giusti L, Iacconi P, Ciregia F, Giannaccini G, Donatini GL, Basolo F, Miccoli P, Pinchera A, Lucacchini A. Fine-Needle Aspiration of Thyroid Nodules: Proteomic Analysis To Identify Cancer Biomarkers. J Proteome Res 2008, 9:4079-4088.
21. Ehmann M, Felix K, Hartmann D, Schnölzer M, Nees M, Vorderwülbecke S, Bogumil R, Büchler MW, Friess H. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 2007, 2:205-214.
22. Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, O'Kane DJ. Comparison of screening methods in the detection of bladder cancer. J Urol 1999, 2:388-394.
23. Chao D, Freedland SJ, Pantuck AJ, Zisman A, Belldegrun AS. Bladder Cancer 2000: Molecular Markers for the Diagnosis of Transitional Cell Carcinoma. Rev Urol 2001, 2:85-93.
24. Kozak KR, Su F, Whitelegge JP, Faull K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005, 17:4589-4596.
25. Ai J, Tan Y, Ying W, Hong Y, Liu S, Wu M, Qian X, Wang H. Proteome analysis of hepatocellular carcinoma by laser capture microdissection. Proteomics 2006, 2:538-546.
26. Roche Y, Pasquier D, Rambeaud JJ, Seigneurin D, Duperray A. Fibrinogen mediates bladder cancer cell migration in an ICAM-1-dependent pathway. Thromb Haemost 2003, 6:1089-1097.
27. Koukourakis MI, Giatromanolaki A, Sivridis E, . Tumour and Angiogenesis Research Group Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cells in non-small cell lung cancer and other epithelial malignant tumors. Tumour Biol 2003, 4:199-202. Tumour and Angiogenesis Research Group.
28. Chen Y, Zhang H, Xu A, Li N, Liu J, Liu C, Lv D, Wu S, Huang L, Yang S, He D, Xiao X. Elevation of serum l-lactate dehydrogenase B correlated with the clinical stage of lung cancer. Lung Cancer 2006, 1:95-102.
29. Hazzaa SM, Elashry OM, Afifi IK. Clusterin as a diagnostic and prognostic marker for transitional cell carcinoma of the bladder. Pathol Oncol Res 2010, 1:101-109.
30. Miyake H, Gleave M, Kamidono S, Hara I. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 2002, 1:150-154.
31. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst 2004, 5:353-356.
32. Ahmed N, Oliva KT, Barker G, Hoffmann P, Reeve S, Smith IA, Quinn MA, Rice GE. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Proteomics 2005, 17:4625-4636.
33. Montironi R, Mazzucchelli R, Scarpelli M, Lopez-Beltran A, Cheng L. Morphological diagnosis of urothelial neoplasms. J Clin Pathol 2008, 1:3-10.
34. Merril CR, Goldman D, Sedman SA, Ebert MH. Ultrasensitive stain for proteins in polyacrylamide gels shows regional variation in cerebrospinal fluid proteins. Science 1981, 211:1437-1438. 10.1126/science.6162199, 6162199.